BioVie (BIVI) 10-K 30 Sep 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 25, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	001-39015
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Entity Tax Identification Number	46-2510769
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	680 W Nye Lane Suite 204
Entity Address, City or Town	Carson City
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89703
City Area Code	(775)
Local Phone Number	888-3162
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	BIVI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 20,590,705
Entity Common Stock, Shares Outstanding		7,956,660
Documents Incorporated by Reference [Text Block]	Portions of the Registrant’s definitive proxy statement relating to its 2024 annual meeting of stockholders (the “2024 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement was filed with the U.S. Securities and Exchange Commission on September 27, 2024.
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	274
Auditor Name	EisnerAmper LLP
Auditor Location	Iselin

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2024	Jun. 30, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 23,843,798	$ 19,460,883
Investments in U.S. Treasury Bills (available-for-sale)		14,477,726
Prepaid and other current assets	204,392	102,526
Total current assets	24,048,190	34,041,135
Operating lease right-of-use assets, net	406,726	80,789
Intangible assets, net	407,718	637,095
Goodwill	345,711	345,711
TOTAL ASSETS	25,208,345	35,104,730
CURRENT LIABILITIES:
Accounts payable and accrued expenses	3,586,912	3,476,259
Other current liabilities		48,385
Current portion of operating lease liabilities	60,343	44,909
Current portion of note payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024 and $894,926 at June 30, 2023	5,701,210	9,105,074
Warrant liability	3,771	894,280
Embedded derivative liability		925,762
Total current liabilities	9,352,236	14,494,669
Operating lease liabilities, net of current portion	349,894	42,505
Note payable, net of current portion, financing cost, unearned premium and  discount of $0 and $227,268 at June 30, 2024 and June 30, 2023, respectively.		5,227,270
TOTAL LIABILITIES	9,702,130	19,764,444
STOCKHOLDERS' EQUITY :
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2024 and June 30, 2023, respectively; 6,216,398 shares issued of which 6,190,072 shares are outstanding at June 30, 2024; and 3,645,183 shares issued of which 3,642,895 shares outstanding at June 30, 2023	6,229	3,643
Additional paid in capital	349,732,674	316,385,759
Accumulated other comprehensive income		176,591
Accumulated deficit	(334,232,661)	(301,225,705)
Treasury stock	(27)	(2)
Total stockholders' equity	15,506,215	15,340,286
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 25,208,345	$ 35,104,730

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Unearned premium and discount current	$ 701,210	$ 894,926
Unearned premium and discount	$ 0	$ 227,268
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	6,216,398	3,645,183
Common stock, shares outstanding	6,190,072	3,642,895

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
OPERATING EXPENSES:
Amortization of intangible assets	$ 229,377	$ 229,377
Research and development expenses	23,100,394	33,299,503
Selling, general and administrative expenses	8,849,814	11,551,568
TOTAL OPERATING EXPENSES	32,179,585	45,080,448
LOSS FROM OPERATIONS	(32,179,585)	(45,080,448)
OTHER (INCOME) EXPENSE:
Change in fair value of derivative liabilities	(1,816,271)	1,437,481
Interest expense	2,893,922	4,300,150
Interest income	(1,136,703)	(562,264)
TOTAL OTHER (INCOME) EXPENSE, NET	(59,052)	5,175,367
NET LOSS	(32,120,533)	(50,255,815)
Deemed dividend related to ratchet adjustment to warrants	886,423
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (33,006,956)	$ (50,255,815)
NET LOSS PER COMMON SHARE
- Basic	$ (7.30)	$ (15.47)
- Diluted	$ (7.30)	$ (15.47)
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING
- Basic	4,518,533	3,248,349
- Diluted	4,518,533	3,248,349
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (33,006,956)	$ (50,255,815)
Other comprehensive (loss) income
Unrealized gain on available-for-sale investments		176,591
Reclassification of unrealized gains on available-for-sale investments upon settlement	(176,591)
Total other comprehensive (loss) income	(176,591)	176,591
Comprehensive loss	$ (33,183,547)	$ (50,079,224)

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stocks [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2022	$ 2,496	$ 254,638,329			$ (250,969,890)	$ 3,670,935
Beginning balance, shares at Jun. 30, 2022	2,498,408
Stock - based compensation - stock options		4,222,845				4,222,845
Stock-based compensation - restricted stock units	$ 21	1,780,028	$ (2)			1,780,047
Stock-based compensation - restricted stock units, Shares	21,518		(2,288)
Stock-based compensation - issuance of common stock for services rendered	$ 5	372,495				372,500
Stock-based compensation - issuance of common stock for services rendered, shares	5,000
Cashless exercise of options	$ 3	(3)
Cashless exercise of options, Shares	2,256
Cashless exercise of warrants
Cashless exercise of warrants, Shares	359
Proceeds from exercise of options		2,240				2,240
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	80
Proceeds from issuance of common stock, net of costs of  $2,908,141	$ 754	49,464,349				49,465,103
Proceeds from issuance of common stock, net of costs, shares	753,925
Proceeds from issuance of common stock, net of costs of  $94,160 - Related Party	$ 364	5,905,476				5,905,840
Proceeds from issuance of common stock, net of costs of Related Party, shares	363,636
Unrealized gain on available-for-sale investments				176,591		176,591
Net Loss					(50,255,815)	(50,255,815)
Ending balance, value at Jun. 30, 2023	$ 3,643	316,385,759	$ (2)	176,591	(301,225,705)	15,340,286
Ending balance, shares at Jun. 30, 2023	3,645,183		(2,288)
Stock - based compensation - stock options		2,823,764				2,823,764
Stock-based compensation - restricted stock units		1,763,450				1,763,450
Stock-based compensation - restricted stock units, Shares
Issuance of common stock from vesting of restricted stock units	$ 122	(97)	$ (25)
Issuance of common stock from vesting of restricted stock units, shares	122,395		(24,038)
Stock-based compensation - issuance of common stock for services rendered	$ 15	72,885				72,900
Stock-based compensation - issuance of common stock for services rendered, shares	15,000
Deemed dividend for ratchet adjustment to warrants		886,423			(886,423)
Relcassification of unrealized gains on available-for-sale investments upon settlement				(176,591)		(176,591)
Issuance of additional shares for fractional shares effected by the reverse split
Issuance of additional shares for fractional shares effected by the reverse split, shares	71
Proceeds from issuance of common stock, net of costs of  $2,908,141	$ 2,449	27,800,490				27,802,939
Proceeds from issuance of common stock, net of costs, shares	2,433,749
Net Loss					(32,120,533)	(32,120,533)
Ending balance, value at Jun. 30, 2024	$ 6,229	$ 349,732,674	$ (27)		$ (334,232,661)	$ 15,506,215
Ending balance, shares at Jun. 30, 2024	6,216,398		(26,326)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (32,120,533)	$ (50,255,815)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets	229,377	229,377
Stock based compensation - restricted stock units	1,763,450	1,780,047
Stock based compensation expense - stock options	2,823,764	4,222,845
Stock based compensation expense - stock issued	72,900	372,500
Amortization of financing costs	108,751	170,219
Accretion of unearned loan discount	1,023,145	1,601,445
Accretion of loan premium	236,970	421,994
Realized gain on maturity of available-for sale	(223,865)
Non-cash lease expense from right-of-use assets	49,346	37,465
Gain on termination of operating lease	(5,215)
Change in fair value of derivative liabilities	(1,816,271)	1,437,481
Changes in operating assets and liabilities:
Prepaid and other assets	(101,866)	39,915
Accounts payable and accrued expenses	110,653	1,033,455
Operating lease liabilities	(47,245)	(38,884)
Other current liabilities	(48,385)	(1,304,925)
Net cash used in operating activities	(27,945,024)	(40,252,881)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from (purchases of) U.S. Treasury Bills (available-for-sale)	14,525,000	(14,301,135)
Net cash provided by (used in) investing activities	14,525,000	(14,301,135)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	27,802,939	49,465,103
Payments of note payable	(10,000,000)
Proceeds from exercise of stock options		2,240
Net proceeds from issuance of common stock - Related Party		5,905,840
Net cash provided by financing activities	17,802,939	55,373,183
Net increase in cash and cash equivalents	4,382,915	819,167
Cash and cash equivalents, beginning of period	19,460,883	18,641,716
Cash and cash equivalents, end of period	23,843,798	19,460,883
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	1,525,056	2,106,491
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:
Right-of-use assets obtained in exchange for lease obligations	432,192
Unrealized gain on U.S. Treasury Bills (available-for-sale)		176,591
Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement	176,591
Deemed dividend of ratchet adjustment to warrants	$ 886,423

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (32,120,533)	$ (50,255,815)

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Background Information

Background Information	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background Information	1. Background Information BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021 . Neurodengenerative Disease Program In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits activation of inflammatory actions extracellular single-regulated kinase (“ERK”) and nuclear factor kappa-light-chain-enhancer of activated B cells (“NFκB”) (including interactions with tumor necrosis factor (“TNF”) signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. NE3107 does not interfere with their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of AD and PD. Alzheimer’s Disease (NCT05083260) On November 29, 2023, the Company announced the analysis of its unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate AD. The study has co-primary endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1:1 versus placebo, to receive sequentially 5 mg of NE3107 orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally twice daily. Upon trial completion, as the Company began the process of unblinding the trial data, the Company found significant deviation from protocol and current good clinical practices (“cGCPs”) violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level of suspected improprieties led the Company to exclude all patients from these sites and to refer the sites to the FDA Office of Scientific Investigations (“OSI”) for potential further action. After the patient exclusions, 81 patients remained in the Modified Intent to Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial and were verified to take study drug from pharmacokinetic data. The trial was originally designed to be 80% powered with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients has left the trial underpowered for the primary endpoints. In the Per-Protocol population, which included those patients who completed the trial and who were further verified to have taken the study drug (based on pharmacokinetic data), an observed descriptive change from baseline appeared to suggest a slowing of cognitive loss; these same patients experienced an advantage in age deceleration vs. placebo as measured by DNA epigenetic change. Age deceleration is used by longevity researchers to measure the difference between the patient’s biological age, in this case as measured by the Horvath DNA methylation Skin Blood Clock, relative to the patient’s actual chronological age. This test was a non-primary/secondary endpoint, other-outcome measure, done via blood test collected at week 30 (end of study). Additional DNA methylation data continues to be collected and analyzed. Parkinson’s Disease (NCT05083260) The Phase 2 study of bezisterim (NE3107) for the treatment of PD (NCT05083260), completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and bezisterim (NE3107). Forty-five patients with a defined L-dopa “off state” were randomized 1:1 to placebo: bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives: 1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions of bezisterim (NE3107) with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met. Long COVID Program In April 2024, the Company announced the grant of a clinical trial award of up to $13.1 million from the DOD, awarded through the Peer Reviewed Medical Research Program (“PRMRP”) of the Congressionally Directed Medical Research Programs (“CDMRP”). The award can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess bezisterim (NE3107) for the treatment of neurological symptoms that are associated with long COVID. The Company anticipates the trial to commence by early 2025. Liver Disease Program In liver disease, our investigational drug candidate BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. In June 2021, the Company initiated a Phase 2 study (NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment cycles) combined with standard-of-care (“SOC”), compared to SOC alone, for the treatment of refractory ascites. The primary endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared to a pre-treatment period. In March 2023, the Company announced enrollment was paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment period. In June 2023, the Company requested and subsequently received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The BIV201 development program was initiated by LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin). to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2024, the Company had working capital of approximately $ 14.7 23.8 15.5 334.2 The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and accounting for income taxes. Actual results could differ from those estimates. Cash and cash equivalents Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less. Investments in U.S. Treasury Bills Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other comprehensive income in the accompanying statements of operations and comprehensive loss. Concentration of Credit Risk in the Financial Service Industry As of June 30, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations. Fair value measurement of assets and liabilities We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions. The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments. Prepaid and other assets Prepaid and other assets consist of prepayments of certain expenses and a security deposit paid in connection with a lease agreement. Leases The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease payments as expense on a straight-line basis over the lease term. Research and Development Research and development expenses consist primarily of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract research and facility costs. Income Taxes The Company uses the asset and liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses. The Company recognizes uncertainty in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to all tax positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty. Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30, 2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented. The table below shows the potential shares of common stock, presented based on amounts outstanding at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Schedule of dilutive securities were excluded from the computation of diluted loss per share June 30, 2024 June 30, 2023 Number of Shares Number of Shares Stock Options 518,076 395,286 Warrants 1,932,029 777,029 Restricted Stock Units 40,291 59,646 Notes payable conversion option 71,633 71,633 Total 2,562,029 1,303,594 Stock-based Compensation The Company has accounted for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) Topic 718 – “Stock Compensation” (“ASC 718”) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The Company recognizes forfeitures as they occur. Goodwill Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company’s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company’s routine business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023. Impairment of Long-Lived Assets Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023. Reverse stock split up The company effected a 1:10 reverse split of the issued and outstanding shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders’ approval was obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split. Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASU’s”). There were no recent ASU’s that are expected to have a material impact on our balance sheets or statements of operations and comprehensive loss. In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This amendment replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements. In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures. This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions. Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard. The adoption of this standard is not expected to have a material impact on our financial statements.

Investments in U.S. Treasury Bi

Investments in U.S. Treasury Bills available-for-sale	12 Months Ended
	Jun. 30, 2024
Investments In U.s. Treasury Bills Available-for-sale
Investments in U.S. Treasury Bills available-for-sale	4. Investments in U.S. Treasury Bills available-for-sale The following is a summary of the U.S. Treasury Bills held at June 30, 2023: Schedule of U.S. treasury bills held Amortized Cost Basis Gross Unrealized Gain Gross Unrealized loss Fair Value Total Accumulated Other Comprehensive Income U.S. Treasury Bills due in 3 - 6 months $ 14,301,136 $ 176,591 $ — $ 14,477,726 $ 176,591 During the fiscal year ended June 30, 2023, the Company purchased a total of approximately $ 46 223,865

Intangible Assets

Intangible Assets	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of June 30, 2024 and 2023: Schedule of intangible assets June 30, 2024 June 30, 2023 Intellectual Property $ 2,293,770 $ 2,293,770 Less: Accumulated Amortization (1,886,052 ) (1,656,675 ) Intellectual Property, Net $ 407,718 $ 637,095 Amortization expense amounted to $ 229,377 10 Estimated future amortization expense is as follows: Schedule of future amortization expense Year ending June 30, 2025 $ 229,377 2026 178,341 Finite lived intangible assets, net $ 407,718

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions Equity Transactions with Acuitas On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s largest stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of 363,636 886,423 10.65 18.20 10.00 3.5 4.4% 95.0% On August 15, 2022, the Company received net proceeds of approximately $5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the “Existing Registration Rights Agreement”), to amend the definition of “Registrable Securities” in the Existing Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.

Notes Payable

Notes Payable	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	7. Notes Payable On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan provided for an additional $5 million to be available to the Company on or prior to September 15, 2022, subject to the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.00% 8.50% The Loan Agreement required monthly interest-only payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays equal monthly payments of principal, plus accrued interest, until the Loan’s maturity date when all remaining principal and accrued interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal amount of the Loan that is prepaid after the interest-only period. At the Loan’s maturity date, or on the date of the prepayment of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and Tranche 2, which amounts to $850,000 (the “Loan Premium”). The Loan Agreement includes a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s Common Stock at a conversion price of $69.80 per share (the “Conversion Option”). On the Closing Date, the Company issued to Avenue warrants to purchase 36,101 shares of Common Stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $58.20. The Avenue Warrants are exercisable until November 30, 2026. The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes, approximately $ 1.4 2.2 3.6 390,000 850,000 Total interest expense for the year ended June 30, 2024 was approximately $ 2.9 1.5 109,000 1.0 237,000 Total interest expense for the year ended June 30, 2023 was approximately $ 4.3 2.1 170,000 422,000 As of June 30, 2024, the remaining principal balance of $ 5.0 10 The following is a summary of the Notes Payable as of June 30, 2024 and 2023: Current portion of Notes Payable Schedule of note payable June 30, 2024 June 30, 2023 Current portion of Notes Payable $ 5,000,000 $ 10,000,000 Less: debt financing costs (11,820 ) (108,751 ) Less: unearned discount (111,212 ) (1,023,145 ) Plus: accretion of Loan Premium 824,242 236,970 Current portion of Notes Payable, net of financing costs, unearned premium and discount $ 5,701,210 $ 9,105,074 Non-current portion of Notes Payable June 30, 2024 June 30, 2023 Notes Payable $ - $ 5,000,000 Less: debt financing costs - (11,820 ) Less: unearned discount - (111,212 ) Plus: accretion of Loan Premium - 350,302 Notes Payable, net of the current portion financing costs, unearned premium and discount $ - $ 5,227,270 Estimated future amortization expense and accretion of Loan Premium is as follows: Schedule of estimated future amortization expense and accretion of premium Unearned Discount Debt Financing Costs Loan Premium Year ending June 30, 2025 $ 111,212 $ 11,820 $ 25,758 Total $ 111,212 $ 11,820 $ 25,758

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements At June 30, 2024 and 2023, the estimated fair value of derivative liabilities measured on a recurring basis are as follows: Schedule of derivative liabilities at fair value Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 3,771 $ 3,771 Derivative liability - Conversion Option - - - - Total derivative liabilities $ - $ - $ 3,771 $ 3,771 Fair Value Measurements at June 30, 2023 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 894,280 $ 894,280 Derivative liability - Conversion option - - 925,762 925,762 Total derivative liabilities $ - $ - $ 1,820,042 $ 1,820,042 The following table presents the activity for level 3 liabilities measured at fair value using unobservable inputs for the years ended June 30, 2024 and 2023: Fair value, liabilities measured on recurring basis Derivative liability - Warrants Derivative liability - Conversion Option Balance at June 30, 2022 $ 194,531 $ 188,030 Additions to level 3 liabilities - - Change in in fair value of level 3 liabilities 699,749 737,732 Transfer in and/or out of level 3 - - Balance at June 30, 2023 $ 894,280 $ 925,762 Additions to level 3 liabilities - - Change in in fair value of level 3 liabilities (890,509 ) (925,762 ) Transfer in and/or out of level 3 - - Balance at June 30, 2024 $ 3,771 $ - The fair values of derivative liabilities for the Avenue Warrants and Conversion Option at June 30, 2024 in the accompanying balance sheet, were approximately $3,800 and approximately zero, respectively. The total change in the fair value of the derivative liabilities totaled approximately $(1.8) million and $1.4 million for the years ended June 30, 2024, and 2023, respectively; and accordingly, was recorded in the accompanying statements of operations and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at June 30, 2024 included the closing stock price of $ 4.00 58.20 2.4 4.6% 82.0% 69.80 5 5.38% 91.0% Derivative liability – Avenue Warrants The Avenue Warrants were not considered to be indexed to the Company’s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompanying balance sheets at June 30, 2024 and 2023. The Black Scholes model was used to calculate the fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants are recorded at their fair values at the date of issuance and remeasured at each subsequent reporting period end date. Embedded derivative liability – Conversion Option The Conversion Option is accounted for as an embedded derivative liability and required bifurcation from the Loan amount. The Black Scholes model was used to calculate the fair value of the Conversion Option to bifurcate it from the Loan. Financial assets As of June 30, 2024, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories. Measured at fair value on a recurring basis Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Cash $ 12,763,941 $ - $ - $ 12,763,941 U.S. Treasury Bills due in 3 months or less at purchase 11,079,857 - - 11,079,857 Total $ 23,843,798 $ - $ - $ 23,843,798 Fair Value Measurements at June 30, 2023 Level 1 Level 2 Level 3 Total Cash $ 6,304,543 $ - $ - $ 6,304,543 U.S. Treasury Bills due in 3 months or less at purchase 13,156,340 - - 13,156,340 U.S. Treasury Bills due in 3 - 6 months at purchase 14,477,726 - - 14,477,726 Total $ 33,938,609 $ - $ - $ 33,938,609

Equity Transactions

Equity Transactions	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Equity Transactions	9. Equity Transactions Issuance of common stock for cash On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the year ended June 30, 2024, the Company sold 333,749 9.3 3% 377,000 753,925 49.5 3% 2.0 On March 6, 2024, the Company closed a best efforts public offering (the “Offering”) of 1,500,000 0.001 600,000 1,050,000 10.00 The Common Warrants have an exercise price of $15.00 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. 600,000 Issuance of common stock for services On April 6, 2023, the Company awarded 5,000 74.50 372,500 On May 10, 2024, the Company awarded 15,000 4.86 72,900 Stock Options The following table summarizes the activity relating to the Company’s stock options for the years ended June 30, 2024 and 2023: Schedule of summarizes the activity relating to the Company’s stock options Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value Outstanding at June 30, 2022 339,876 $ 74.20 5.5 $ - Granted 71,467 59.00 8.6 38,610 Options Expired (1,000 ) 286.90 - - Options Canceled (4,967 ) 77.40 Options Exercised (10,090 ) 81.20 - - Outstanding at June 30, 2023 395,286 71.00 6.3 1,067,966 Granted 155,242 11.70 9.8 - Options Expired (640 ) 46.09 - - Options Canceled (31,812 ) 57.19 - - Outstanding at June 30, 2024 518,076 $ 54.11 6.1 $ - Exercisable at June 30, 2024 296,934 $ 66.65 4.9 $ - The fair value of each option grant on the date of grant is estimated using the Black-Scholes model. The following weighted-average assumptions were utilized for the years ended: Schedule of assumptions used June 30, 2024 June 30, 2023 Expected life of options (in years) 6 6 Expected volatility 86.28% 81.65% Risk free interest rate 4.40% 3.82% Dividend Yield 0% 0% The Company recorded stock based compensation expense relating to the vesting of stock options of approximately $ 2.8 4.2 Issuance and modification of restricted stock units and options: On June 21, 2022, the Company awarded 12,452 4,151 4,151 On November 23, 2022, the Company awarded 38,198 61.20 9,550 2,288 On November 23, 2022, the Company issued equity awards for the board of directors’ annual compensation. Four directors received 15,564 61.20 19,500 61.20 1,744,192 On November 9, 2023, the Company issued equity awards for the board of directors’ annual compensation. Four directors received 18,270 30.10 18,325 30.10 4,568 In December 2023, the Company terminated five employees and as part of their severance agreement modified their equity awards that had been granted pursuant to the 2019 Omnibus Plan. The modifications included the acceleration of certain stock option awards to purchase a total of 5,623 shares of common stock (“Accelerated Options”), effective on the December Separation Date, as defined in severance agreement (“Separation Date”), and extended the expiration date for one year from the Separation Date for both the Accelerated Options and any vested and unexercised stock options held by the terminated employees as of the Separation Date. Accordingly, the Company remeasured the Accelerated Options based on the stock price of $15.40 per share at the close on the Separation Date and a one-year extension of the term. The net adjustment for the modification was a net credit of $127,199 and was recognized as an adjustment to stock compensation expense during the year ended June 30, 2024. Additionally, 1,030 vesting RSUs were accelerated as of the Separation date. The modified RSUs were remeasured based on the stock price of $15.40 per share at close on the Separation Date and $15,865, was recorded to additional in stock-based compensation for the year ended June 30, 2024 as a result of the modification. In connection with the separation, the Company canceled 18,396 unvested stock options and 1,030 unvested RSUs. Additionally, the Company canceled an additional 13,416 unvested stock options for employees that voluntarily left the company. In June 2023, the Company issued 14,950 41.10 4,983 In June 2024, the Company issued 85,800 4.74 85,800 21,450 The following table summarizes vesting of restricted stock units: Schedule of vesting of restricted common stock Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at June 30, 2022 12,452 $ 16.90 Granted 68,711 58.87 Vested (21,518 ) 52.70 Unvested at June 30, 2023 59,646 $ 52.40 Issued 104,070 9.16 Vested (122,395 ) 16.94 Canceled (1,030 ) 61.20 Unvested at June 30, 2024 40,291 $ 44.59 The total stock-based compensation expense from restricted stock units for the year ended June 30, 2024 and 2023 was approximately $ 1.8 1.8 Issuance of Common Stock through exercise of Stock Options and Warrants In December 2022, the Company issued 2,209 9,930 76.40 In November 2022, the Company issued 80 80 28.00 In October 2022, the Company issued 359 800 22.50 In May 2023, the Company issued 48 80 31.30 Issuance of Stock Options under the 2019 Omnibus Plan. Pursuant to a former employee’s Separation Agreement, dated April 11, 2022, the Company modified their stock option award granted on August 20, 2021, pursuant to the 2019 Omnibus Plan (“2021 Options Grant”). Pursuant to the terms of the Separation Agreement, effective July 8, 2022 (the “Separation Date”), the Company accelerated the vesting of options scheduled to vest on the first and second anniversary of the grant date as deemed vested (“Accelerated Options”) and after giving effect to the Accelerated Options, extended the exercise period of the total vested outstanding and unexercised options (totaling 7,450 options) to one year following the Separation Date. The unvested portion of the 2021 Option Grant (totaling 4,967 options) was canceled. The modification was remeasured as of July 8, 2022, and the incremental difference in fair value resulted in a net credit to stock based compensation expense of $181,154, due to the original exercise price of $77.40 being greater than the stock price of $18.00 on the remeasurement date, and accordingly was recognized on July 8, 2022. On June 7, 2023, the Company granted stock options to purchase 14,800 20% 80% 57.80 During the fiscal year ended June 30, 2023, the Company granted stock options to purchase a total of 28,617 shares of Common Stock in connection with compensation packages of three new employees. The exercise prices were set at the grant date fair value with vesting terms over a five year period and the options terminate on the earlier of tenth grant date anniversary or the date of which the options are fully exercised. On October 3, 2023, the Company granted stock options to purchase 21,117 20% 80% 34.10 In June 2024, the Company granted stock options to purchase 115,800 33% 67% 2 4.70 Stock Warrants The following table summarizes the warrants activity during the years ended June 30, 2024 and 2023: Summary of warrants activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2022 51,037 $ 61.70 3.8 $ - Granted 727,273 18.20 5.0 - Expired (482 ) 750.00 - - Exercised (800 ) 22.50 - - Outstanding and exercisable at June 30, 2023 777,029 20.60 4.0 18,318,954 Granted 1,755,000 13.14 5.0 - Exercised (600,000 ) 10.00 - - Outstanding and exercisable at June 30, 2024 1,932,029 $ 14.03 4.0 $ - Of the above warrants outstanding at June 30, 2024, 10,138 expire in the fiscal year ending June 30, 2025, 3,518 expire in the fiscal year ending June 30, 2026, 763,373 expire in the fiscal year ending June 30, 2027 and 1,155,000 expire in the fiscal year ending June 30, 2029.

Leases

Leases	12 Months Ended
	Jun. 30, 2024
Leases
Leases	10. Leases Office Leases The Company pays an annual rent of $2,200 for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term, commenced on October 1, 2022 and has been subsequently renewed for another year at the same rate. The Company’s San Diego office lease at 5090 Shoreham Place Suite 212, San Diego, CA 92122 which commenced on March 1, 2022, was for a term of 38 months with a base monthly rate of $4,300, and annual increases of three percent. In February 2024, the Company amended the lease agreement which allowed the Company to vacate the then current space and move to a larger space at Suite 206. The current monthly base rate for the new office space is $9,685, with an annual increase of four percent. The term for the new office lease is 60 months and commenced on February 12, 2024. The lease that was in place for the 5090 Shoreham Place Suite 212 office was effectively extinguished upon the commencement of the new office space lease on February 12, 2024, resulting in the write off of the corresponding remaining right-of-use asset and operating lease liability of $ 56,909 62,124 5,215 Total operating lease expense for the years ended June 30, 2024 and 2023 of approximately $ 78,000 52,000 The right-of-use asset, net and current and non-current portion of the operating lease liabilities included in the accompanying balance sheets are as follows: Schedule of deferred tax assets June 30, 2024 June 30, 2023 Assets Operating lease, right-of-use asset, net $ 406,726 $ 80,789 Liabilities Current portion of operating lease liability $ 60,343 $ 44,909 Operating lease liability, net of current portion 349,894 42,505 Total operating lease liability $ 410,237 $ 87,414 At June 30, 2024, the future estimated minimum lease payments under non-cancelable operating leases are as follows: Schedule of future estimated minimum lease payments under non-cancelable operating leases Year ending June 30, 2025 $ 117,915 2026 122,042 2027 126,313 2028 130,734 2029 77,796 Total minimum lease payments 574,800 Less amount representing interest (164,563 ) Present value of future minimum lease payments 410,237 Less current portion of operating lease liability (60,343 ) Operating lease liability, net of current portion $ 349,894 Total cash paid for amounts included in the measurement of lease liabilities were $ 83,910 50,600 The weighted average remaining lease term and discount rate as of June 30, 2024 and 2023 were as follows: Schedule of weighted average remaining lease term and discount rate June 30, 2024 June 30, 2023 Weighted average remaining lease term (Years) Operating lease 4.6 1.8 Weighted average discount rate Operating lease 15.00 % 10.75 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Royalty Agreements Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year. Shareholder class action complaint On January 19, 2024, a purported shareholder class action complaint, captioned Eric Olmstead v. BioVie Inc. et al. Way v. BioVie Inc. et al. In re BioVie Inc. Securities Litigation in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The class action is on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023 and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. The defendants filed a motion to dismiss the amended complaint on August 21, 2024. The Company believes the lawsuit is without merit and intends to defend the case vigorously. At this early stage of the proceedings, the Company is unable to make any prediction regarding the outcome of the litigation. No adjustment or accruals have been reflected in the accompanying financial statements.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2024
Employee Benefit Plan
Employee Benefit Plan	12. Employee Benefit Plan On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate. Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan. The Company made contributions into the plan of approximately $ 153,200 171,900

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes Significant components of the Company’s deferred tax assets (liabilities) are as follows: Schedule of deferred tax assets June 30, 2024 June 30, 2023 Deferred tax assets (liabilities): Tax loss carryforward $ 51,429,074 $ 48,080,664 Intangible assets (114,161 ) (189,854 ) Stock based compensation 5,860,272 4,575,852 R&D capitalized 12,467,969 8,171,276 Valuation Allowance (69,643,154 ) (60,637,938 ) Net deferred tax assets $ - $ - At June 30, 2024 and 2023, the Company has recorded a full valuation against its net deferred tax assets of approximately $ 69.6 60.6 9.0 At June 30, 2024, the Company had a Net Operating Loss (“NOL”) carryforward of approximately $ 184 2032 to 2037 The Company has no current tax expense due to its net losses and a full valuation allowance. Reconciliation of the differences between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2024 and 2023 is as follows: Schedule of effective income tax rate reconciliation 2024 2023 Income tax expense at federal statutory rate 21 % 21 % State taxes, net of federal benefit 7 % 7 % Change in valuation allowance (28 )% (28 )% Effective tax rate - -

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On September 25, 2024, the Company closed a best efforts public offering (the “September 2024 Offering”) of 1,360,800 0.0001 600,000 1,960,800 1.53 The September 1.53 3.0 560,000 98,040 1.91

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and accounting for income taxes. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.
Investments in U.S. Treasury Bills	Investments in U.S. Treasury Bills Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other comprehensive income in the accompanying statements of operations and comprehensive loss.
Concentration of Credit Risk in the Financial Service Industry	Concentration of Credit Risk in the Financial Service Industry As of June 30, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.
Fair value measurement of assets and liabilities	Fair value measurement of assets and liabilities We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Inputs are unobservable inputs based on our assumptions. The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.
Prepaid and other assets	Prepaid and other assets Prepaid and other assets consist of prepayments of certain expenses and a security deposit paid in connection with a lease agreement.
Leases	Leases The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease payments as expense on a straight-line basis over the lease term.
Research and Development	Research and Development Research and development expenses consist primarily of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract research and facility costs.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses. The Company recognizes uncertainty in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to all tax positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30, 2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented. The table below shows the potential shares of common stock, presented based on amounts outstanding at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Schedule of dilutive securities were excluded from the computation of diluted loss per share June 30, 2024 June 30, 2023 Number of Shares Number of Shares Stock Options 518,076 395,286 Warrants 1,932,029 777,029 Restricted Stock Units 40,291 59,646 Notes payable conversion option 71,633 71,633 Total 2,562,029 1,303,594
Stock-based Compensation	Stock-based Compensation The Company has accounted for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) Topic 718 – “Stock Compensation” (“ASC 718”) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The Company recognizes forfeitures as they occur.
Goodwill	Goodwill Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company’s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company’s routine business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023.
Reverse stock split up	Reverse stock split up The company effected a 1:10 reverse split of the issued and outstanding shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders’ approval was obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASU’s”). There were no recent ASU’s that are expected to have a material impact on our balance sheets or statements of operations and comprehensive loss. In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This amendment replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements. In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures. This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions. Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard. The adoption of this standard is not expected to have a material impact on our financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of dilutive securities were excluded from the computation of diluted loss per share	Schedule of dilutive securities were excluded from the computation of diluted loss per share June 30, 2024 June 30, 2023 Number of Shares Number of Shares Stock Options 518,076 395,286 Warrants 1,932,029 777,029 Restricted Stock Units 40,291 59,646 Notes payable conversion option 71,633 71,633 Total 2,562,029 1,303,594

Investments in U.S. Treasury _2

Investments in U.S. Treasury Bills available-for-sale (Tables)	12 Months Ended
	Jun. 30, 2024
Investments In U.s. Treasury Bills Available-for-sale
Schedule of U.S. treasury bills held	Schedule of U.S. treasury bills held Amortized Cost Basis Gross Unrealized Gain Gross Unrealized loss Fair Value Total Accumulated Other Comprehensive Income U.S. Treasury Bills due in 3 - 6 months $ 14,301,136 $ 176,591 $ — $ 14,477,726 $ 176,591

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets June 30, 2024 June 30, 2023 Intellectual Property $ 2,293,770 $ 2,293,770 Less: Accumulated Amortization (1,886,052 ) (1,656,675 ) Intellectual Property, Net $ 407,718 $ 637,095
Schedule of future amortization expense	Schedule of future amortization expense Year ending June 30, 2025 $ 229,377 2026 178,341 Finite lived intangible assets, net $ 407,718

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of note payable	Schedule of note payable June 30, 2024 June 30, 2023 Current portion of Notes Payable $ 5,000,000 $ 10,000,000 Less: debt financing costs (11,820 ) (108,751 ) Less: unearned discount (111,212 ) (1,023,145 ) Plus: accretion of Loan Premium 824,242 236,970 Current portion of Notes Payable, net of financing costs, unearned premium and discount $ 5,701,210 $ 9,105,074 Non-current portion of Notes Payable June 30, 2024 June 30, 2023 Notes Payable $ - $ 5,000,000 Less: debt financing costs - (11,820 ) Less: unearned discount - (111,212 ) Plus: accretion of Loan Premium - 350,302 Notes Payable, net of the current portion financing costs, unearned premium and discount $ - $ 5,227,270
Schedule of estimated future amortization expense and accretion of premium	Schedule of estimated future amortization expense and accretion of premium Unearned Discount Debt Financing Costs Loan Premium Year ending June 30, 2025 $ 111,212 $ 11,820 $ 25,758 Total $ 111,212 $ 11,820 $ 25,758

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of derivative liabilities at fair value	Schedule of derivative liabilities at fair value Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 3,771 $ 3,771 Derivative liability - Conversion Option - - - - Total derivative liabilities $ - $ - $ 3,771 $ 3,771 Fair Value Measurements at June 30, 2023 Level 1 Level 2 Level 3 Total Derivative liability - Warrants $ - $ - $ 894,280 $ 894,280 Derivative liability - Conversion option - - 925,762 925,762 Total derivative liabilities $ - $ - $ 1,820,042 $ 1,820,042
Fair value, liabilities measured on recurring basis	Fair value, liabilities measured on recurring basis Derivative liability - Warrants Derivative liability - Conversion Option Balance at June 30, 2022 $ 194,531 $ 188,030 Additions to level 3 liabilities - - Change in in fair value of level 3 liabilities 699,749 737,732 Transfer in and/or out of level 3 - - Balance at June 30, 2023 $ 894,280 $ 925,762 Additions to level 3 liabilities - - Change in in fair value of level 3 liabilities (890,509 ) (925,762 ) Transfer in and/or out of level 3 - - Balance at June 30, 2024 $ 3,771 $ -
Measured at fair value on a recurring basis	Measured at fair value on a recurring basis Fair Value Measurements at June 30, 2024 Level 1 Level 2 Level 3 Total Cash $ 12,763,941 $ - $ - $ 12,763,941 U.S. Treasury Bills due in 3 months or less at purchase 11,079,857 - - 11,079,857 Total $ 23,843,798 $ - $ - $ 23,843,798 Fair Value Measurements at June 30, 2023 Level 1 Level 2 Level 3 Total Cash $ 6,304,543 $ - $ - $ 6,304,543 U.S. Treasury Bills due in 3 months or less at purchase 13,156,340 - - 13,156,340 U.S. Treasury Bills due in 3 - 6 months at purchase 14,477,726 - - 14,477,726 Total $ 33,938,609 $ - $ - $ 33,938,609

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of summarizes the activity relating to the Company’s stock options	Schedule of summarizes the activity relating to the Company’s stock options Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value Outstanding at June 30, 2022 339,876 $ 74.20 5.5 $ - Granted 71,467 59.00 8.6 38,610 Options Expired (1,000 ) 286.90 - - Options Canceled (4,967 ) 77.40 Options Exercised (10,090 ) 81.20 - - Outstanding at June 30, 2023 395,286 71.00 6.3 1,067,966 Granted 155,242 11.70 9.8 - Options Expired (640 ) 46.09 - - Options Canceled (31,812 ) 57.19 - - Outstanding at June 30, 2024 518,076 $ 54.11 6.1 $ - Exercisable at June 30, 2024 296,934 $ 66.65 4.9 $ -
Schedule of assumptions used	Schedule of assumptions used June 30, 2024 June 30, 2023 Expected life of options (in years) 6 6 Expected volatility 86.28% 81.65% Risk free interest rate 4.40% 3.82% Dividend Yield 0% 0%
Schedule of vesting of restricted common stock	Schedule of vesting of restricted common stock Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at June 30, 2022 12,452 $ 16.90 Granted 68,711 58.87 Vested (21,518 ) 52.70 Unvested at June 30, 2023 59,646 $ 52.40 Issued 104,070 9.16 Vested (122,395 ) 16.94 Canceled (1,030 ) 61.20 Unvested at June 30, 2024 40,291 $ 44.59
Summary of warrants activity	Summary of warrants activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding and exercisable at June 30, 2022 51,037 $ 61.70 3.8 $ - Granted 727,273 18.20 5.0 - Expired (482 ) 750.00 - - Exercised (800 ) 22.50 - - Outstanding and exercisable at June 30, 2023 777,029 20.60 4.0 18,318,954 Granted 1,755,000 13.14 5.0 - Exercised (600,000 ) 10.00 - - Outstanding and exercisable at June 30, 2024 1,932,029 $ 14.03 4.0 $ -

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2024
Leases
Schedule of deferred tax assets	Schedule of deferred tax assets June 30, 2024 June 30, 2023 Assets Operating lease, right-of-use asset, net $ 406,726 $ 80,789 Liabilities Current portion of operating lease liability $ 60,343 $ 44,909 Operating lease liability, net of current portion 349,894 42,505 Total operating lease liability $ 410,237 $ 87,414
Schedule of future estimated minimum lease payments under non-cancelable operating leases	Schedule of future estimated minimum lease payments under non-cancelable operating leases Year ending June 30, 2025 $ 117,915 2026 122,042 2027 126,313 2028 130,734 2029 77,796 Total minimum lease payments 574,800 Less amount representing interest (164,563 ) Present value of future minimum lease payments 410,237 Less current portion of operating lease liability (60,343 ) Operating lease liability, net of current portion $ 349,894
Schedule of weighted average remaining lease term and discount rate	Schedule of weighted average remaining lease term and discount rate June 30, 2024 June 30, 2023 Weighted average remaining lease term (Years) Operating lease 4.6 1.8 Weighted average discount rate Operating lease 15.00 % 10.75 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	Schedule of deferred tax assets June 30, 2024 June 30, 2023 Deferred tax assets (liabilities): Tax loss carryforward $ 51,429,074 $ 48,080,664 Intangible assets (114,161 ) (189,854 ) Stock based compensation 5,860,272 4,575,852 R&D capitalized 12,467,969 8,171,276 Valuation Allowance (69,643,154 ) (60,637,938 ) Net deferred tax assets $ - $ -
Schedule of effective income tax rate reconciliation	Schedule of effective income tax rate reconciliation 2024 2023 Income tax expense at federal statutory rate 21 % 21 % State taxes, net of federal benefit 7 % 7 % Change in valuation allowance (28 )% (28 )% Effective tax rate - -

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative)	Jun. 30, 2024 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ 14,700,000
Cash and cash equivalent	23,800,000
Stockholders' equity	15,500,000
Accumulated deficit	$ 334,200,000

Significant Accounting Polici_4

Significant Accounting Policies (Details) - shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,562,029	1,303,594
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	518,076	395,286
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,932,029	777,029
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	40,291	59,646
Notespayable Conversion Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	71,633	71,633

Investments in U.S. Treasury _3

Investments in U.S. Treasury Bills Available for Sale (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Schedule of Investments [Line Items]
Total Accumulated Other Comprehensive Income		$ 176,591
US Treasury Bill Securities [Member]
Schedule of Investments [Line Items]
Amortized Cost Basis		14,301,136
Gross Unrealized Gain		176,591
Gross Unrealized loss
Fair Value		14,477,726
Total Accumulated Other Comprehensive Income		$ 176,591

Investments in U.S. Treasury _4

Investments in U.S. Treasury Bills available-for-sale (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Investments In U.s. Treasury Bills Available-for-sale
Number of stock purchased		$ 46,000,000
Realized gain on maturity of available-for sale	$ 223,865

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	$ 2,293,770	$ 2,293,770
Less: Accumulated Amortization	(1,886,052)	(1,656,675)
Intellectual Property, Net	$ 407,718	$ 637,095

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 229,377
2026	178,341
Finite lived intangible assets, net	$ 407,718	$ 637,095

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expenses	$ 229,377	$ 229,377
Useful life	10 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 25, 2024	Mar. 06, 2024	Jun. 30, 2023	Oct. 31, 2022	Jul. 15, 2022
Related Party Transaction [Line Items]
Common stock, shares issued	6,216,398	1,360,800		3,645,183
Deemed dividend	$ 886,423
Stock price			$ 10
Exercise price		$ 1.53
Warrants [Member]
Related Party Transaction [Line Items]
Stock price	$ 10.65				$ 22.50
Remaining term	3 years 6 months
Risk free rate	4.40%
Volatility	95%
Warrants [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Exercise price	$ 18.20
Warrants [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Exercise price	$ 10
Acuitas Group Holdings, LLC [Member]
Related Party Transaction [Line Items]
Common stock, shares issued						363,636

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Debt Disclosure [Abstract]
Current portion of Notes Payable	$ 5,000,000	$ 10,000,000
Less: debt financing costs	(11,820)	(108,751)
Less: unearned discount	(111,212)	(1,023,145)
Plus: accretion of Loan Premium	824,242	236,970
Current portion of Notes Payable, net of financing costs, unearned premium and discount	5,701,210	9,105,074
Notes Payable		5,000,000
Less: debt financing costs		(11,820)
Less: unearned discount		(111,212)
Plus: accretion of Loan Premium		350,302
Notes Payable, net of the current portion financing costs, unearned premium and discount		$ 5,227,270

Notes Payable (Details 1)

Notes Payable (Details 1)	Jun. 30, 2024 USD ($)
Unearned Discount [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
2025	$ 111,212
Total	111,212
Financing Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
2025	11,820
Total	11,820
Loan Accretion Premium [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
2025	25,758
Total	$ 25,758

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Debt Instrument [Line Items]
Interest rate	8.50%
Fair value of warrants	$ 1,400,000
Fair value of embedded conversion option	2,200,000
Unearned discount	1,000,000	$ 3,600,000
Direct financing cost	390,000,000
Unamortized premium recognized	850,000,000
Interest expense	2,900,000	4,300,000
Interest payment	1,500,000	2,100,000
Amortization of financing costs	109,000,000	170,000,000
Accretion of loan premium	237,000,000	422,000,000
Remaining principal balance	5,000,000
Repayments of notes payable	$ 10,000,000
Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate	7%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	$ 3,771	$ 1,820,042
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	3,771	1,820,042
Derivative liability - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	3,771	894,280
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives	3,771	894,280	$ 194,531
Derivative Liability Conversion Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives		925,762
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total derivatives		$ 925,762	$ 188,030

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	$ 1,820,042
Balance at ending	3,771	$ 1,820,042
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	1,820,042
Balance at ending	3,771	1,820,042
Derivative liability - Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	894,280
Balance at ending	3,771	894,280
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	894,280	194,531
Additions to level 3 liabilities
Change in in fair value of level 3 liabilities	(890,509)	699,749
Transfer in and/or out of Level 3
Balance at ending	3,771	894,280
Derivative Liability Conversion Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	925,762
Balance at ending		925,762
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	925,762	188,030
Additions to level 3 liabilities
Change in in fair value of level 3 liabilities	(925,762)	737,732
Transfer in and/or out of Level 3
Balance at ending		$ 925,762

Fair Value Measurements (Deta_3

Fair Value Measurements (Details 2) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 23,843,798	$ 33,938,609
US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	11,079,857	13,156,340
U.S. Treasury Bills due in 3 months or less at purchase [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		14,477,726
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	23,843,798	33,938,609
Fair Value, Inputs, Level 1 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	11,079,857	13,156,340
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury Bills due in 3 months or less at purchase [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		14,477,726
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury Bills due in 3 months or less at purchase [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member] | US Treasury Bill Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury Bills due in 3 months or less at purchase [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	12,763,941	6,304,543
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	12,763,941	6,304,543
Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total

Fair Value Measurements (Deta_4

Fair Value Measurements (Details Narrative) - $ / shares	12 Months Ended
	Jun. 30, 2024	Mar. 06, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price		$ 10
Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 4
Exercise Price	$ 58.20
Term	2 years 4 months 24 days
Risk Free Interest Rate	4.60%
Volatility Rate	82%
Derivative liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 69.80
Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Term	5 months
Risk Free Interest Rate	5.38%
Volatility Rate	91%

Equity Transactions (Details)

Equity Transactions (Details) - Stock Options [Member]	12 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares
Offsetting Assets [Line Items]
Options outstanding at beginning | shares	395,286	339,876
Weighted average exercise price, options outstanding at beginning | $ / shares	$ 71	$ 74.20
Weighted remaining average contractual term, beginning		5 years 6 months
Aggregate intrinsic value, outstanding at beginning | $	$ 1,067,966
Options granted | shares	155,242	71,467
Weighted average exercise price, granted | $ / shares	$ 11.70	$ 59
Weighted remaining average contractual term, granted	9 years 9 months 18 days	8 years 7 months 6 days
Aggregate intrinsic value, granted | $		$ 38,610
Options expired | shares	(640)	(1,000)
Weighted average exercise price, expired | $ / shares	$ 46.09	$ 286.90
Options canceled | shares	(31,812)	(4,967)
Weighted average exercise price, canceled | $ / shares	$ 57.19	$ 77.40
Options exercised | shares		(10,090)
Weighted average exercise price, exercised | $ / shares		$ 81.20
Weighted remaining average contractual term, beginning	6 years 3 months 18 days
Options outstanding at ending | shares	518,076	395,286
Weighted average exercise price, options outstanding at ending | $ / shares	$ 54.11	$ 71
Weighted remaining average contractual term, ending	6 years 1 month 6 days
Aggregate intrinsic value, outstanding at ending | $		$ 1,067,966
Options exercisable | shares	296,934
Weighted average exercise price, options exercisable | $ / shares	$ 66.65
Weighted average remaining contractual term, options exercisable	4 years 10 months 24 days

Equity Transactions (Details 1)

Equity Transactions (Details 1) - Stock Options [Member]	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Offsetting Assets [Line Items]
Expected life of options (In years)	6 years	6 years
Expected volatility	86.28%	81.65%
Risk free interest rate	4.40%	3.82%
Dividend Yield	0%	0%

Equity Transactions (Details 2)

Equity Transactions (Details 2) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Equity [Abstract]
Number of shares unvested at beginning	59,646	12,452
Weighted average grant date fair value per share unvested at beginning	$ 52.40	$ 16.90
Number of shares, Issued	104,070
Weighted average grant date fair value per share, Issued	$ 9.16
Number of shares, Granted		68,711
Weighted average grant date fair value per share, Granted		$ 58.87
Number of shares, Vested	(122,395)	(21,518)
Weighted average grant date fair value per share, Vested	$ 16.94	$ 52.70
Number of shares, Canceled	(1,030)
Weighted average grant date fair value per share, Canceled	$ 61.20
Number of shares unvested at ending	40,291	59,646
Weighted average grant date fair value per share unvested at ending	$ 44.59	$ 52.40

Equity Transactions (Details 3)

Equity Transactions (Details 3) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares, exercised	104,070
Weighted average exercise price, exercised	$ 9.16
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares, beginning	777,029	51,037
Weighted average exercise price, beginning	$ 20.60	$ 61.70
Weighted average remaining life (Years)	4 years	3 years 9 months 18 days
Aggregate intrinsic value, outstanding at beginning	$ 18,318,954
Number of shares, granted	1,755,000	727,273
Weighted average exercise price, granted	$ 13.14	$ 18.20
Weighted average remaining life (Years), granted	5 years	5 years
Number of shares, expired		(482)
Weighted average exercise price, expired		$ 750
Number of shares, exercised	(600,000)	(800)
Weighted average exercise price, exercised	$ 10	$ 22.50
Number of shares, ending	1,932,029	777,029
Weighted average exercise price, ending	$ 14.03	$ 20.60
Weighted average remaining life (Years)	4 years
Aggregate intrinsic value, outstanding at ending		$ 18,318,954

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)							1 Months Ended								12 Months Ended
	Jun. 07, 2024	May 10, 2024	Mar. 06, 2024	Nov. 09, 2023	Oct. 03, 2023	Apr. 06, 2023	Jun. 30, 2024	Jun. 30, 2023	May 31, 2023	Dec. 31, 2022	Nov. 30, 2022	Nov. 23, 2022	Oct. 31, 2022	Jun. 21, 2022	Jun. 30, 2024	Jun. 30, 2023	Sep. 25, 2024
Class of Stock [Line Items]
Public offering			1,500,000
Common stock, par value			$ 0.001				$ 0.0001	$ 0.0001							$ 0.0001	$ 0.0001	$ 0.0001
Share price			$ 10
Stock-based compensation expense															$ 2,823,764	$ 4,222,845
Total compensation cost												$ 1,744,192
Stock based compensation - restricted stock units															1,800,000	1,800,000
Stock Options [Member]
Class of Stock [Line Items]
Stock-based compensation expense															$ 2,800,000	$ 4,200,000
Weighted average exercise price, options grants															$ 11.70	$ 59
Vendor [Member]
Class of Stock [Line Items]
Share price		$ 4.86				$ 74.50
Stock issued during period for service		15,000				5,000
Stock-based compensation expense		$ 72,900				$ 372,500
Employees [Member] | Equity Option [Member]
Class of Stock [Line Items]
Stock option to purchase							115,800
Weighted average exercise price, options grants							$ 4.70
Weighted average contractual term, granted (in years)							2 years
Certain Employees [Member] | Equity Option [Member]
Class of Stock [Line Items]
Stock option to purchase	14,800
Weighted average exercise price, options grants	$ 57.80
New Employee [Member] | Equity Option [Member]
Class of Stock [Line Items]
Stock option to purchase					21,117
Weighted average exercise price, options grants					$ 34.10
New Employee [Member] | Equity Option [Member] | Minimum [Member]
Class of Stock [Line Items]
Awarded Vested rights, percentage	20%				20%		33%
New Employee [Member] | Equity Option [Member] | Maximum [Member]
Class of Stock [Line Items]
Awarded Vested rights, percentage	80%				80%		67%
Prefunded Warrants [Member]
Class of Stock [Line Items]
Stock option to purchase			600,000
Number of stock exercised															600,000
Common Warrant [Member]
Class of Stock [Line Items]
Stock option to purchase			1,050,000
Restricted Stock Units (RSUs) [Member] | President And C E O [Member] | N2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted								14,950				38,198		12,452	4,151	4,151
Rsu granted, grant date fair value								$ 41.10				$ 61.20
Shares issued over the vesting period								4,983								9,550
Shares for tax withholdings																2,288
Restricted Stock Units (RSUs) [Member] | Four Directors [Member] | N2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted												15,564
Rsu granted, grant date fair value												$ 61.20
Restricted Stock Units (RSUs) [Member] | Three Directors [Member] | N2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted												19,500
Rsu granted, grant date fair value												$ 61.20
Restricted Stock Units (RSUs) [Member] | Four Director [Member] | N2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted				18,270
Rsu granted, grant date fair value				$ 30.10
Shares issued over the vesting period															4,568
Restricted Stock Units (RSUs) [Member] | Two Directors [Member] | N2019 Omnibus Incentive Equity Plan [Member]
Class of Stock [Line Items]
Rsu granted				18,325
Rsu granted, grant date fair value				$ 30.10
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Class of Stock [Line Items]
Rsu granted							85,800
Rsu granted, grant date fair value							$ 4.74
Shares issued over the vesting period							85,800
Shares for tax withholdings							21,450
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Issuance of common stock for cash, shares									48	2,209	80
Stock option to purchase									80	9,930	80
Share price									$ 31.30	$ 76.40	$ 28
Warrants [Member]
Class of Stock [Line Items]
Issuance of common stock for cash, shares													359
Stock option to purchase													800
Share price							$ 10.65						$ 22.50		$ 10.65
Common Class A [Member] | Sales Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock for cash, shares															333,749	753,925
Issuance of common stock for cash															$ 9,300,000	$ 49,500,000
Commissions percentage															3%	3%
Issuance costs															$ 377,000	$ 2,000,000

Leases (Details)

Leases (Details) - USD ($)	Jun. 30, 2024	Feb. 12, 2024	Jun. 30, 2023
Leases
Operating lease, right-of-use asset, net	$ 406,726	$ 56,909	$ 80,789
Current portion of operating lease liability	60,343		44,909
Operating lease liability, net of current portion	349,894		42,505
Total operating lease liability	$ 410,237	$ 62,124	$ 87,414

Leases (Details 1)

Leases (Details 1) - USD ($)	Jun. 30, 2024	Feb. 12, 2024	Jun. 30, 2023
Leases
2025	$ 117,915
2026	122,042
2027	126,313
2028	130,734
2029	77,796
Total minimum lease payments	574,800
Less amount representing interest	(164,563)
Present value of future minimum lease payments	410,237	$ 62,124	$ 87,414
Less current portion of operating lease liability	(60,343)		(44,909)
Operating lease liability, net of current portion	$ 349,894		$ 42,505

Leases (Details 2)

Leases (Details 2)	Jun. 30, 2024	Jun. 30, 2023
Leases
Weighted average remaining lease term (Years) Operating leases	4 years 7 months 6 days	1 year 9 months 18 days
Weighted average discount rate Operating leases	15%	10.75%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Feb. 12, 2024
Leases
Right-of-use Asset	$ 406,726	$ 80,789	$ 56,909
Operating Lease Liability	410,237	87,414	$ 62,124
Selling, general and administrative expenses	5,215
Operating lease cost	78,000	52,000
Cash paid for amounts included in measurement of operating lease liabilities	$ 83,910	$ 50,600

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Employee Benefit Plan
Defined benefit plan, plan assets, contributions by employer	$ 153,200	$ 171,900

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Deferred tax assets (liabilities):
Tax loss carryforward	$ 51,429,074	$ 48,080,664
Intangible assets	(114,161)	(189,854)
Stock based compensation	5,860,272	4,575,852
R&D capitalized	12,467,969	8,171,276
Valuation Allowance	(69,643,154)	(60,637,938)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense at federal statutory rate	21%	21%
State taxes, net of federal benefit	7%	7%
Change in valuation allowance	(28.00%)	(28.00%)
Effective tax rate

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Net	$ 69,600,000	$ 60,600,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	9,000,000
Net Operating Loss carryforward	$ 184,000,000
Expirations dates	2032 to 2037

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended
	Sep. 25, 2024	Jun. 30, 2024	Mar. 06, 2024	Jun. 30, 2023
Common stock shares	1,360,800	6,216,398		3,645,183
Common stock per value	$ 0.0001	$ 0.0001	$ 0.001	$ 0.0001
Warrants exercise price	$ 1.53
Proceeds from public offering	$ 3,000,000
Agent fees and offering expenses	$ 560,000
Placement Agents Warrants [Member]
Warrants exercise price	$ 1.91
Warrant issued	98,040
Prefunded Warrants [Member]
Purchase of shares	600,000
Common Warrants [Member]
Common stock per value	$ 1.53
Purchase of shares	1,960,800